Methscopolamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Methscopolamine
DrugBank Accession Number
DB11315
Background

Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 318.392
Monoisotopic: 318.169984677
Chemical Formula
C18H24NO4
Synonyms
  • Methylscopolamine

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia [Dailymed].

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-Benzodiazepine1,2-Benzodiazepine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AclidiniumThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Methscopolamine.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methscopolamine.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Methscopolamine.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Methscopolamine nitrateK0813KQM3V6106-46-3BSQIVYOSLFLSGE-RAFJPFSSSA-N
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Allergy DN IIMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitOralBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31US flag
Allergy DN IIMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitOralBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31US flag
Allergy DN PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitOralBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31US flag
Allergy DN PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitOralBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31US flag
AlleRx Dose PackMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (10 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)KitOralCornerstone Therapeutics Inc.2008-02-012012-10-31US flag
AlleRx Dose PackMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (10 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)KitOralCornerstone Therapeutics Inc.2008-02-012012-10-31US flag
AlleRx Dose Pack DFMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitOralCornerstone Therapeutics Inc.2006-08-012012-10-31US flag
AlleRx Dose Pack DFMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitOralCornerstone Therapeutics Inc.2006-08-012012-10-31US flag
AlleRx Dose Pack PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitOralCornerstone Therapeutics Inc.2006-09-012012-10-31US flag
AlleRx Dose Pack PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitOralCornerstone Therapeutics Inc.2006-09-012012-10-31US flag

Categories

ATC Codes
A03CB01 — Methylscopolamine and psycholepticsS01FA03 — MethylscopolamineA03BB03 — Methylscopolamine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Benzene and substituted derivatives / Piperidines / Morpholines / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds / Oxacyclic compounds / Dialkyl ethers / Epoxides
show 7 more
Substituents
Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
VDR09VTQ8U
CAS number
13265-10-6
InChI Key
LZCOQTDXKCNBEE-IKIFYQGPSA-N
InChI
InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12-,13-,14-,15+,16-,17+/m1/s1
IUPAC Name
(1R,2R,4S,5S,7S)-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium
SMILES
C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1

References

General References
Not Available
PubChem Compound
71183
PubChem Substance
347827965
ChemSpider
21106347
BindingDB
50241132
RxNav
89785
ChEBI
135361
ChEMBL
CHEMBL376897
ZINC
ZINC000100047524
PDBe Ligand
3C0
Wikipedia
Methylscopolamine_bromide
PDB Entries
4u16 / 5yc8 / 5zk8 / 5zkc

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, chewableOral
Tablet, extended releaseOral
LiquidOral
TabletOral
SyrupOral
Tablet, multilayer, extended releaseOral
KitOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0145 mg/mLALOGPS
logP-1.5ALOGPS
logP-3.3ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.06 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity95.63 m3·mol-1ChemAxon
Polarizability33.34 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created on December 03, 2015 16:52 / Updated on May 29, 2021 18:14